Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

tatements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the second half of 2008 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development and our plans and anticipated effects of the transaction described in this press release. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.

Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the inability to consummate the transaction described in this press release or that the transaction will not provide the anticipated benefits described in this press release; general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercializati
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 21, 2015 Research and ... of the "Biomedical Refrigerators and Freezers Market ... and Forecast 2014 - 2022" report to ... refrigerators and freezers market has been segmented based ... blood banks, and others. The others segment includes ...
(Date:7/28/2015)... Tauriga Sciences, Inc. (OTCQB:  TAUG) or ("Tauriga" ... announced that its stockholders approved an increase in the ... Company from 1,000,000,000 to 2,500,000,000 at its Special Meeting ... Law Offices of Nixon Peabody LLP in Midtown Manhattan ... 480,655,929 shares of common stock represented either by proxy ...
(Date:7/28/2015)... BEACH, Calif. , July 28, 2015 /PRNewswire-USNewswire/ ... announced that it has hit a milestone of ... Signafuse was FDA 510(k) cleared in early 2014 ... use in posterolateral spine fusion procedures.  This is ... products, as less than 6% of new synthetic ...
(Date:7/28/2015)... TRIANGLE PARK, N.C., July 28, 2015  United Therapeutics ... financial results for the second quarter ended June 30, ... 300% as compared to the second quarter of ... Roger Jeffs, Ph.D., United Therapeutics, President and Co-Chief ... due to an increase in the number of ...
Breaking Biology Technology:Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Revolutionary Bone Graft Exceeds Expectations 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... MaxCyte, Inc., a,clinical-stage therapeutics company and pioneer ... that Anthony Recupero, Ph.D.,Vice President Business Development ... 2008, at 2:00PM at the BIO-Europe Spring ... will discuss the development of,engineered cell based ...
... continues to advance collaborative research worldwide, ... Biosystems, Inc.,announced today that leading research institutions, ... at the University of,Queensland, and the Biotech ... University of Copenhagen have recently purchased access ...
... 2008 /Xinhua-PRNewswire-FirstCall/ -- China YCT,International Group Inc. (OTC ... subsidiary, Shandong Spring Pharmaceutical Co., Ltd, has,entered into ... Tang,Bioengineering Co. Ltd., effective as of April 4, ... manage the operations of,Shandong Yong Chun Tang, in ...
Cached Biology Technology:Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland 2Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland 3China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier 2China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier 3
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/8/2015)... 8, 2015 The consumer products industry ... must have products such as wearables, smart wallets & other ... biometrics based devices continues to rapidly grow.  Biometrics & Wearable ... NXTD ), Google Inc. (NASDAQ: GOOG ), Apple Inc. ... GoPro, Inc. (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... system have identified a previously unrecognized set of targets and ... center on discovery of signaling molecules that are major players ... to solid tumor growth. The most notable implication of ... than decade to treat non-Hodgkin,s lymphoma, which is a cancer ...
... News media and others interested in the chemical ... series of American Chemical Society (ACS) Webinars, Professional Growth ... treatment market. The session will feature discussion on the ... regulatory requirements for your company, and new opportunities in ...
... helps animals to recognise others by their smell. Researchers ... vasopressin helps the brain differentiate between familiar and new scents. ... suggests that when the hormone fails to function, animals are ... ability to recognise others by smell is crucial in helping ...
Cached Biology News:New cancer-fighting strategy focuses on signaling molecules 2New cancer-fighting strategy focuses on signaling molecules 3ACS webinar features developments in online water and wastewater monitoring 2Hormone study gives scientists a sense of how animals bond 2
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
Biology Products: